Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Abstract Background Treatment of metastatic melanoma patients with immune checkpoint inhibitors is an important standard of care. Side effects are due to immune activation, can affect virtually all organ systems, and are occasionally severe. Although hematologic toxicity has been reported, we presen...

Full description

Bibliographic Details
Main Authors: Andrew Hantel, Brooke Gabster, Jason X. Cheng, Harvey Golomb, Thomas F. Gajewski
Format: Article
Language:English
Published: BMJ Publishing Group 2018-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Melanoma
HLH
Hemophagocytosis
Immune checkpoint
Checkpoint inhibitor
Online Access:http://link.springer.com/article/10.1186/s40425-018-0384-0

Internet

http://link.springer.com/article/10.1186/s40425-018-0384-0

Similar Items